| 4.35 -0.02 (-0.46%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.5 | 1-year : | 7.49 |
| Resists | First : | 5.57 | Second : | 6.42 |
| Pivot price | 5.31 |
|||
| Supports | First : | 4.19 | Second : | 3.49 |
| MAs | MA(5) : | 4.61 |
MA(20) : | 5.39 |
| MA(100) : | 2.74  |
MA(250) : | 2.01 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 9.4 |
D(3) : | 11.8 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 6.42 | Low : | 0.93 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRDF ] has closed above bottom band by 6.3%. Bollinger Bands are 94.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.6 - 4.64 | 4.64 - 4.67 |
| Low: | 4.17 - 4.23 | 4.23 - 4.26 |
| Close: | 4.29 - 4.38 | 4.38 - 4.43 |
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Thu, 14 Mar 2024
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last? - Yahoo Finance
Wed, 13 Mar 2024
Should You Buy Cardiff Oncology Inc (CRDF) Stock After it Is Up 46.27% in a Week? - InvestorsObserver
Fri, 08 Mar 2024
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade) (NASDAQ:CRDF) - Seeking Alpha
Sun, 03 Mar 2024
We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate - Simply Wall St
Fri, 01 Mar 2024
Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results - Yahoo Finance
Thu, 29 Feb 2024
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 4.129e+007 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.501e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 623 % |
| Return on Equity (ttm) | -28.7 % |
| Qtrly Rev. Growth | 488000 % |
| Gross Profit (p.s.) | 11.11 |
| Sales Per Share | -23.9 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.19 |
| Price to Cash Flow | 5.49 |
| Dividend | 0 |
| Forward Dividend | 3.41e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|